Innovhem’s patents have been issued !

by Innovhem | November 8, 2024

Cette actualité appartient aux catégories suivantes : Uncategorized

Innovhem’s patents protect our BIOMARKERS : An important news !
SINGLE CELL QUANTIFICATION OF FETAL HEMOGLOBIN patent has been issued in France, Nigeria and in the US.
And our 2 patents cover INTRAVASCULAR HEMOLYSIS ASSAY in Europe and in the US.
Stay tuned for future important milestones!

Lastest news of Innovhem

Marie Cambot Awarded Chevalier de l’Ordre National du Mérite

October 23, 2025

Paris, France – October 14, 2025 – Innovhem announces its co-founder and CEO Marie Cambot has been awarded Chevalier de l’Ordre National du Mérite....

New publication !

September 11, 2025

Innovhem proudly shares its latest scientific publication in Haematologica Journal, highlighting our commitment to advancing hematology research. In...

Aventure France 2030 !

April 11, 2025

Aventure France 2030 ! 🏆 Hier, à Paris, se tenait le Comité interministériel de l'innovation C2i. Nous sommes fiers de faire partie de...

🚨 Another step forward in the fight against sickle cell disease !

April 8, 2025

Another step forward in the fight against sickle cell disease ! On the occasion of the state visit to France by Their Majesties King Frederik X and...

Innovhem will present new data at the 2024 ASH Annual Meeting

November 15, 2024

Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting. One poster presentation to feature new...

Innovhem paticipates to HEMOPROVE study, sponsored by AP-HP

March 18, 2024

HEMOPROVE is an Open-label One Stage Phase II study sponsored by AP-HP. The investigator hypothesis is that the treatment by Voxelotor (GBT440) will...